DOCSLIB.ORG

(Tinea) Versicolor Infections

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(Tinea) Versicolor Infections This report reflects the best data available at the time the report was prepared, but cau- tion should be exercised in interpreting the data; the results of future studies may require alteration of the conclusions or recommendations set forth in this report. Guidelines of care for superficial mycotic infections of the skin: Pityriasis (tinea) versicolor Guidelines~Outcomes Committee: Lynn A. Drake, MD, Chairman, Scott M. Dinehart, MD, Evan R. Farmer, MD, Robert W. Goltz, MD, Gloria F. Graham, MD, Maria K. Hordinsky, MD, Charles W. Lewis, MD, David M. Pariser, MD, John W. Skouge, MD, Stephen B. Webster, MD, Duane C. Whitaker, MD, Barbara Butler, CPA-SDR Consultant, and Barbara J. Lowery, MPH Task Force: Boni E. Elewski, MD, Chairman, Mervyn L. Elgart, MD, Paul H. Jacobs, MD, Jack L. Lesher, Jr., MD, and Richard K. Scher, MD I. Introduction Guidelines of Care for Superficial Mycotic Infec- The American Academy of Dermatology's Guide- tions of the Skin: Onychomycosis lines/Outcomes Committee is developing guide- Guidelines of Care for Superficial Mycotic Infec- lines of care for our profession. The development tions of the Skin: Piedra of guidelines will promote the continued delivery of Pityriasis (tinea) versicolor is a superficial infection quality care and assist those outside our profession of the stratum comeum by the yeast Malassezia in understanding the complexities and scope of care furfur (syn. Pityrosporum orbiculare). This yeast is provided by dermatologists. For the benefit of part of the normal cutaneous flora. Pityriasis (tinea) members of the American Academy of Dermatol- versicolor is characterized by hyperpigrnented and ogy who practice outside the jurisdiction of the hypopigmented scaly patches, primarily on the United States, the listed treatments may include trunk and proximal extremities. agents that are not currently approved by the U.S. III. Rationale Food and Drag Administration. A. Scope 11. Definition Pityriasis (tinea) versicolor is a common disor- "Guidelines of Care for Superficial Mycotic In- der that affects people of all age groups, but is fections of the Skin: Pityriasis (Tinea) Versicolor" most commonly seen in adults. Infants and is one of six documents addressing superficial my- children can also be affected, but often have an coses. Companion documents in this series include atypical presentation. This disease is typically the following: worse in geographic areas with tropical ambi- Guidelines of Care for Superficial Mycotic Infec- ent temperatures. Multiple factors are known to tions of the Skin: Mucocutaneous Candidiasis contribute to its pathogenesis. Guidelines of Care for Superficial Mycotic Infec- B. Issue tions of the Skin: .Tinea Corporis, Tinea Cruris, Involvement of the cutaneous surface can oc- Tinea Faciei, Tinea Manuum, and Tinea Pedis casionally be extensive, leading to emotional Guidelines of Care for Superficial Mycotic Infec- distress because of appearance. Symptoms tions of the Skin: Tinea Capitis and Tinea Bar- vary from none to severe pruritus. Although bae numerous therapies are available, recurrences frequently occur after treatment, especially in Reprint requests: AmericanAcademy of Dermatology, P.O. Box4014, tropical climates. Schaumburg, IL 60168-4014. (Providedfree of charge) IV. Diagnostic criteria J AM ACADD~ra~TOL 1996;34:287-9. A. Clinical Copyright 1996 by the American Academyof Dermatology,Inc. 1. History may include the following: 0190-9622/96 $5.00+ 0 16/1/69828 a. General medical condition, especially if 287 Journal of the American Academy of Dermatology 2,88 Drake et al. February 1996 use of oral antifungals is considered, examination, the diagnosis can often be estab- may include the following: lished. Greater diagnostic accuracy occurs ff t) Hepatic disease the clinical diagnosis is verified by laboratory 2) Renal disease tests. This verification is especially important 3) Endocrine disease--diabetes melli- when the use of systemic therapy is anticipated. tus Simple, inexpensive tests that can be performed 4) Use of systemic medications in the physician's office at the time of the pa- 5) Other tient visit may yield immediate results. Such b. Duration, progression to point of max- tests include, but are not limited to, the follow- imal severity ing: c. Seasonal variation 1. Potassium hydroxide preparation (KOH) d. Current treatment(s), topical and sys- Scale from the affected area is placed on a temic, of glass slide, and 10% to 15% KOH is added 1) Pityriasis versicolor with or without dimethyl sulfoxide 2) Other diseases (DMSO). If DMSO is included, gentle e. Past treatment(s), topical and systemic, heating is generally not necessary. A fungal of stain such as Chlorazol Black E, or Parker's 1) Pityriasis versicolor blue-black ink may be added to highlight 2) Other diseases the hyphae and yeast cells. A confirmatory f. Other skin disorders, especially but not KOH preparation would reveal short, limited to the following: stubby hyphae and yeast cells. Patients may lj' Atopy, personal or familial (because have a predominance of either. of occasional irritation to topical an- 2. Wood's light examination to demonstrate tifungal agents) extent of involvement 2) Seborrheic dermalilis 3. Other stains g. Drug allergies Other stains may be used to identify the h. Habitual use of heavy oils on skin hyphae and yeast cells. These stains in- i. Other chde, but are not limited to, the following: 2. Physical examination may include the fol- a. Paragon multiple stain lowing: b. Other a. General physical examination as indi- 4. Studies for differential diagnosis may in- cated elude the following: b. Location a. Fungal culture to exclude other my- 1) Anterior aspect of the chest coses M. furfur does not grow on rou- 2) Back fine agars without growth supplements 3) Extremities and is therefore not routinely cultured. 4) Face, neck (more common in chil- b. Skin biopsy to differentiate pitydasis dren) versicolor from other dermatoses c. Clim'cal appearance c. Other 1) Hyperpigr~nted lesions 5. Other 2) Hypopigmented lesions C. Inappropriate diagnostic tests 3) Erythematons lesions Routine allergy testing d. Extent of involvement D. Exceptions e. Gradation Not applicable 1) Mild E. Evolving diagnostic tests 2) Moderate Not applicable 3) Severe V. Recommendations f. Associated findings A. Treatment 1) Posfinflammatory hyperpigmenta- Topical treatment alone may be indicated for tion and hypopigmentation most patients. Systemic treatment may be indi- 2) Pruritus cated for persons with extensive involvement, 3) Excoriations with recunent infections, and in whom topical 4) Other agents as sole therapy have failed. Systemic g. Other therapy may be used with or without topical B. Diagnostic tests agents or may be used alone in patients intol- After review of the patient history and physical erant to topical treatment. Journal of the American Academy of Dermatology Volume 34, Number 2, Part 1 Drake et al. 289 1. Medical VII. Disclaimer a. Topical antifungal products include, but Adherence to these guidelines will not ensure suc- are not limited to, the following: cessful treatment in every situation. Further, these 1) Imidazoles guidelines should not be deemed inclusive of all 2) Ciclopirox olamine proper methods of care or exclusive of other meth- 3) Miscellaneous ods of care reasonably directed to obtaining the a) Selenium sulfide shampoos, lo- same results. The ultimate judgement regarding the tions propriety of any specific procedure must be made b) Zinc pyrithione shampoos by the physician in light of all the circumstances c) Sulfur preparations presented by the individual patient. For the benefit d) Salicylic acid preparations of members of the American Academy of Derma- e) Propylene glycol lotions tology who practice outside the jurisdiction of the f) Benzoyl peroxide United States, the listed treatments may include g) Other agents that are not currently approved by the U.S. 4) Other Food and Drug Administration. b. Systemic therapy (see V.A. above) 1) Ketoconazole Appendix. Bibliography 2) Evolving Albright SD, Hitch JM. Rapid treatment of tinea versicolorwith a a) Fluconazole selenium sulfide shampoo. Arch Dermatol 1965;93:460-2. b) Itraconazole Bickers DR. Anfifimgal therapy: potential interactions with other classes of drugs. J AM ACAI9DERMATOL 1994;31;$87-90. Other c) Brodell RT, Elewski BE. Clinical Pearl: systemic antifungal drugs 3) Other and drug interactions. J AM ACADDERMATOL 1995;33:259-60. 2. Surgical Delescluse J. Itraconazolein tinea versicolor, a review. J AM Ao_Ao Not applicable DERMATOL1990;23:551-4. 3. Other Faergemann J. Treatmentof pityfiasis versicolorwith itraconazole: a double-blind placebo-controlled study. Mycoses 1988;31: B. Miscellaneous 377-9. 1. Follow-up Faergemann J, Djarv L. Tinea versicolor, treatment and prophy- Follow-up examinations may be indicated, laxis with ketoconazole. Curls 1982;30:542-5, 550. depending on extent, severity, and tolerance Faergemann J, FredriekssonT. An open trial of the effect of a zinc to medications, as well as the need to aug- pyrithioneshampoo in tinea versicolor.Curls 1980;25:667,669. Faergemann J, FredrikssonT. Propyleneglycol in the treatment Of ment or alternate treatment on the basis of tinea versicolor. Acta Derm Venereol (Stockh) 1980;60:92-3. clinical response. Intervals between visits Gupta AK, Sauder DN, Shear NH. Anfifungalagents: an overview. will vary, depending on, but not limited to, Part I. J AM ACAD DERMATOL1994;30:677-98. the severity of the problem and the intensity Gupta AK, Sauder DN, Shear NH. Antifungalagents: an overview. of the treatment. Part IL J AM AcAD DF.RMATOL1994;30:911-33. Hay RJ. Antifungal drugs on the horizon. J AM ACADDERMATOL 2. Monitoring of patients receiving systemic 1994;31:$82-5. therapy Hay RJ, Midgeley G. Short course ketoconazoletherapy in pityr- Periodic monitoring of hepatic, renal, and iasis versicolor. Clin Exp Dermatol 1984;9:571-3. hematopoietic function may be indicated in Hemgmdez-P6rezE. A comparison between one and two weeks' patients treated with systemic antifungals. treatment with bifonazole in pityriasis versicolor. J AM ACAD DERMATOL 1986;14:561-4. 3. Drug interactions Lesher JL Jr, Smith JG Jr.
Load more

Recommended publications
  • Ringworm & Other Human Fungal Infections
    Ringworm & Other Human Fungal Infections McKenzie Pediatrics Ringworm, medically known as Tinea Corporis, is a common skin infection of childhood, and is not caused by a worm at all, but rather by a fungus. It is usually easily treated, and should not be seen as a source of social stigma. It is just one of many types of Tinea infections that affect humans. Tinea is a widespread group of fungal infections caused by dermatophytes. It is second to acne as the most frequently reported skin disease in the United States. Infection may occur through contact with infected humans (by way of shared combs, brushes, hats, pillows, clothing, or bedding) and animals (especially dogs and cats), soil, or inanimate objects. Tinea should be suspected in any red, scaly, itchy, and enlarging rash. Tinea is a superficial infection of the skin (Tinea Corporis), scalp (Tinea Capitis), nails (Tinea Unguium), groin (Tinea Cruris), hands (Tinea Manuum) or feet (Tinea Pedis). There are three types and 27 varieties of dermatophytes that cause human Tinea: Trichophyton, Epidermophyton, and Microsporum. Tinea Corporis (Ringworm) causes smooth and bare skin, typically surrounded by a raised, red, scaly “ring”. Lesions are often solitary, though may be multiple, and even overlapping. It is not nearly as common as what it is most often mistaken for: nummular eczema, a variety of eczema that causes round or oval scaly patches but without a clear area in the center. Nummular eczema tends to be more numerous, and is often less itchy than Ringworm. Topical treatments that are available over-the-counter usually work quite well for Tinea Corporis.
    [Show full text]
  • Diagnosis and Treatment of Tinea Versicolor Ronald Savin, MD New Haven, Connecticut
    ■ CLINICAL REVIEW Diagnosis and Treatment of Tinea Versicolor Ronald Savin, MD New Haven, Connecticut Tinea versicolor (pityriasis versicolor) is a common imidazole, has been used for years both orally and top­ superficial fungal infection of the stratum corneum. ically with great success, although it has not been Caused by the fungus Malassezia furfur, this chronical­ approved by the Food and Drug Administration for the ly recurring disease is most prevalent in the tropics but indication of tinea versicolor. Newer derivatives, such is also common in temperate climates. Treatments are as fluconazole and itraconazole, have recently been available and cure rates are high, although recurrences introduced. Side effects associated with these triazoles are common. Traditional topical agents such as seleni­ tend to be minor and low in incidence. Except for keto­ um sulfide are effective, but recurrence following treat­ conazole, oral antifungals carry a low risk of hepato- ment with these agents is likely and often rapid. toxicity. Currently, therapeutic interest is focused on synthetic Key Words: Tinea versicolor; pityriasis versicolor; anti­ “-azole” antifungal drugs, which interfere with the sterol fungal agents. metabolism of the infectious agent. Ketoconazole, an (J Fam Pract 1996; 43:127-132) ormal skin flora includes two morpho­ than formerly thought. In one study, children under logically discrete lipophilic yeasts: a age 14 represented nearly 5% of confirmed cases spherical form, Pityrosporum orbicu- of the disease.3 In many of these cases, the face lare, and an ovoid form, Pityrosporum was involved, a rare manifestation of the disease in ovale. Whether these are separate enti­ adults.1 The condition is most prevalent in tropical tiesN or different morphologic forms in the cell and semitropical areas, where up to 40% of some cycle of the same organism remains unclear.: In the populations are affected.
    [Show full text]
  • (Sporanox Capsules) 280-A
    PRIOR AUTHORIZATION CRITERIA BRAND NAME (generic) SPORANOX ORAL CAPSULES (itraconazole) Status: CVS Caremark Criteria Type: Initial Prior Authorization Policy FDA-APPROVED INDICATIONS Sporanox (itraconazole) Capsules are indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: 1. Blastomycosis, pulmonary and extrapulmonary 2. Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and 3. Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy. Specimens for fungal cultures and other relevant laboratory studies (wet mount, histopathology, serology) should be obtained before therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, antiinfective therapy should be adjusted accordingly. Sporanox Capsules are also indicated for the treatment of the following fungal infections in non-immunocompromised patients: 1. Onychomycosis of the toenail, with or without fingernail involvement, due to dermatophytes (tinea unguium), and 2. Onychomycosis of the fingernail due to dermatophytes (tinea unguium). Prior to initiating treatment, appropriate nail specimens for laboratory testing (KOH preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis of onychomycosis. Compendial Uses Coccidioidomycosis2,3
    [Show full text]
  • Jp Xvii the Japanese Pharmacopoeia
    JP XVII THE JAPANESE PHARMACOPOEIA SEVENTEENTH EDITION Official from April 1, 2016 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the convenience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 64 Pursuant to Paragraph 1, Article 41 of the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices (Law No. 145, 1960), the Japanese Pharmacopoeia (Ministerial Notification No. 65, 2011), which has been established as follows*, shall be applied on April 1, 2016. However, in the case of drugs which are listed in the Pharmacopoeia (hereinafter referred to as ``previ- ous Pharmacopoeia'') [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as ``new Pharmacopoeia'')] and have been approved as of April 1, 2016 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as of March 31, 2016 as those exempted from marketing approval pursuant to Paragraph 1, Article 14 of the Same Law (hereinafter referred to as ``drugs exempted from approval'')], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on September 30, 2017.
    [Show full text]
  • Table 1B 2005 Community Prescription Numbers, Together with Government
    TABLE 1B 2005 COMMUNITY PRESCRIPTION NUMBERS, TOGETHER WITH GOVERNMENT AND PATIENT COSTS FOR PBS-LISTED DRUGS Table 1B includes an estimate of community (non-public hospital) prescription numbers for the 2005 calendar year, costs (government and patient contribution) for the items with a four digit PBS/RPBS code, together with the defined daily dose (DDD) where assigned. There is no cost information available for items with a five digit Amfac drug code. Table 1 exclude the presentation of information on any item with an estimated community use of less than 110 prescriptions in 2005. The prescription items are arranged by ATC code on generic name, and by form and strength using either the PBS drug code (4 digit) or, for non-PBS items, the Amfac drug code (5 digit). Consult the index (page 255) by generic drug name to obtain the appropriate ATC code. An index by 2nd level of the ATC classification follows: ALIMENTARY TRACT AND METABOLISM PAGE NO A01 STOMATOLOGICAL PREPARATIONS 181 A02 DRUGS FOR ACID RELATED DISORDERS 182 A03 DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS 185 A04 ANTIEMETICS AND ANTINAUSEANTS 187 A05 BILE AND LIVER THERAPY 188 A06 LAXATIVES 189 A07 ANTIDIARRHOEALS, INTESTINAL 191 ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS A08 ANTIOBESITY PREPARATIONS, EXCLUDING DIET PRODUCTS 193 A09 DIGESTIVES, INCLUDING ENZYMES 194 A10 DRUGS USED IN DIABETES 195 A11 VITAMINS 197 A12 MINERAL SUPPLEMENTS 199 A14 ANABOLIC AGENTS FOR SYSTEMIC USE 200 177 BLOOD AND BLOOD FORMING ORGANS B01 ANTITHROMBOTIC AGENTS 201 B02 ANTIHAEMORRHAGICS 203 B03
    [Show full text]
  • EUROPEAN PHARMACOPOEIA 10.2 Index 1. General Notices
    EUROPEAN PHARMACOPOEIA 10.2 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of
    [Show full text]
  • Diagnosis and Management of Tinea Infections JOHN W
    Diagnosis and Management of Tinea Infections JOHN W. ELY, MD, MSPH; SANDRA ROSENFELD, MD; and MARY SEABURY STONE, MD University of Iowa Carver College of Medicine, Iowa City, Iowa Tinea infections are caused by dermatophytes and are classified by the involved site. The most common infections in prepubertal children are tinea corporis and tinea capitis, whereas adolescents and adults are more likely to develop tinea cruris, tinea pedis, and tinea unguium (onychomycosis). The clinical diagnosis can be unreliable because tinea infections have many mimics, which can manifest identical lesions. For example, tinea corporis can be confused with eczema, tinea capitis can be confused with alopecia areata, and onychomycosis can be confused with dystrophic toe- nails from repeated low-level trauma. Physicians should confirm suspected onychomycosis and tinea capitis with a potassium hydroxide preparation or culture. Tinea corporis, tinea cruris, and tinea pedis generally respond to inex- pensive topical agents such as terbinafine cream or butenafine cream, but oral antifungal agents may be indicated for extensive disease, failed topical treatment, immunocompromised patients, or severe moccasin-type tinea pedis. Oral terbinafine isfirst-line therapy for tinea capitis and onychomycosis because of its tolerability, high cure rate, and low cost. However, kerion should be treated with griseofulvin unless Trichophyton has been documented as the pathogen. Failure to treat kerion promptly can lead to scarring and permanent hair loss. (Am Fam Physician. 2014;90(10):702- 710. Copyright © 2014 American Academy of Family Physicians.) More online he term tinea means fungal infec- (Figure 1). Lesions may be single or multi- at http://www. tion, whereas dermatophyte refers ple and the size generally ranges from 1 to aafp.org/afp.
    [Show full text]
  • Tinea Versicolor Treatment
    47 REGENT STREET, KOGARAH, NSW 2217 T: 9553 0700 www.southderm.com.au What causes timea versicolor? Tinea Versicolor Tineo versicolor is caused by an overgrowth of yeast (a type of fungus) on the skin. Tinea versicolor (also known as pityriasis versicolor) is Everyone has yeast growing on their skin, but a type of fungal infection caused by an overgrowth of when it grows too much it can affect the pigment yeast on the skin. The yeast interferes with the normal and cause tinea versicolor. Yeast on the skin pigmentation (colour) of the skin, causing small spots may overgrow if you are exposed to hot, humid or patches of discoloured skin. Tinea versicolor can weather or if you sweat a lot, have oily skin or develop at any age but is more common in teenagers a weakened immune system. People who live and young adults. It affects people of all skin colours, in tropical or subtropical climates may have a particularly those who live in tropical or subtropical recurrence of the condition every year, especially areas of the world. during spring. How is tinea versicolor diagnosed? What does timea versicolor look like? A dermatologist can diagnose tinea versicolor by the appearance of the spots or patches on your The first sign of tinea versicolor is often a rash of spots on the skin. They may confirm the diagnosis by taking a skin. As the yeast infection spreads the spots may combine scraping of affected skin (a biopsy) and to form patches. The patches of affected skin can appear examining it under a microscope.
    [Show full text]
  • Views in Allergy and Immunology
    CLINICAL REVIEWS IN ALLERGY AND IMMUNOLOGY Dermatology for the Allergist Dennis Kim, MD, and Richard Lockey, MD specific laboratory tests and pathognomonic skin findings do Abstract: Allergists/immunologists see patients with a variety of not exist (Table 1). skin disorders. Some, such as atopic and allergic contact dermatitis, There are 3 forms of AD: acute, subacute, and chronic. are caused by abnormal immunologic reactions, whereas others, Acute AD is characterized by intensely pruritic, erythematous such as seborrheic dermatitis or rosacea, lack an immunologic basis. papules associated with excoriations, vesiculations, and se- This review summarizes a select group of dermatologic problems rous exudates. Subacute AD is associated with erythematous, commonly encountered by an allergist/immunologist. excoriated, scaling papules. Chronic AD is associated with Key Words: dermatology, dermatitis, allergy, allergic, allergist, thickened lichenified skin and fibrotic papules. There is skin, disease considerable overlap of these 3 forms, especially with chronic (WAO Journal 2010; 3:202–215) AD, which can manifest in all 3 ways in the same patient. The relationship between AD and causative allergens is difficult to establish. However, clinical studies suggest that extrinsic factors can impact the course of disease. Therefore, in some cases, it is helpful to perform skin testing on foods INTRODUCTION that are commonly associated with food allergy (wheat, milk, llergists/immunologists see patients with a variety of skin soy, egg, peanut, tree nuts, molluscan, and crustaceous shell- Adisorders. Some, such as atopic and allergic contact fish) and aeroallergens to rule out allergic triggers that can dermatitis, are caused by abnormal immunologic reactions, sometimes exacerbate this disease.
    [Show full text]
  • The Medical Effects of Mold Exposure
    AAAAI Position Statement February 2006 Environmental and occupational respiratory disorders Position paper The medical effects of mold exposure Robert K. Bush, MD, FAAAAI,a Jay M. Portnoy, MD, FAAAAI,b Andrew Saxon, MD, FAAAAI,c Abba I. Terr, MD, FAAAAI,d and Robert A. Wood, MDe Madison, Wis, Kansas City, Mo, Los Angeles and Palo Alto, Calif, and Baltimore, Md Exposure to molds can cause human disease through several well-defined mechanisms. In addition, many new mold-related Abbreviations used illnesses have been hypothesized in recent years that remain ABPA: Allergic bronchopulmonary aspergillosis largely or completely unproved. Concerns about mold exposure CRS: Chronic rhinosinusitis and its effects are so common that all health care providers, HP: Hypersensitivity pneumonitis particularly allergists and immunologists, are frequently faced MVOC: Volatile organic compound made by mold with issues regarding these real and asserted mold-related VOC: Volatile organic compound illnesses. The purpose of this position paper is to provide a state-of-the-art review of the role that molds are known to play in human disease, including asthma, allergic rhinitis, allergic bronchopulmonary aspergillosis, sinusitis, and hypersensitivity occupational respiratory pneumonitis. In addition, other purported mold-related pathology and are typically without specificity for the Environmental and illnesses and the data that currently exist to support them are involved fungus–fungal product purported to cause the carefully reviewed, as are the currently available approaches illness. disorders for the evaluation of both patients and the environment. In this position paper we will review the state of the (J Allergy Clin Immunol 2006;117:326-33.) science of mold-related diseases and provide interpre- Key words: Mold, fungi, hypersensitivity, allergy, asthma tation as to what is and what is not supported by scientific evidence.
    [Show full text]
  • Ketoconazole and Posaconazole Selectively Target HK2 Expressing Glioblastoma Cells
    Author Manuscript Published OnlineFirst on October 15, 2018; DOI: 10.1158/1078-0432.CCR-18-1854 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Ketoconazole and Posaconazole Selectively Target HK2 Expressing Glioblastoma Cells Sameer Agnihotri1*^, Sheila Mansouri2^, Kelly Burrell2, Mira Li2, Jeff Liu2, 3, Romina Nejad2, Sushil Kumar2, Shahrzad Jalali2, Sanjay K. Singh2, Alenoush Vartanian2, Eric Xueyu Chen4, Shirin Karimi2, Olivia Singh2, Severa Bunda2, Alireza Mansouri5, Kenneth D. Aldape2, Gelareh Zadeh2, 5* 1. Children's Hospital of Pittsburgh, Department of Neurological Surgery, University of Pittsburgh School of Medicine, 4401 Penn Ave. Pittsburgh, Pennsylvania 15224, USA 2. MacFeeters-Hamilton Center for Neuro-Oncology Research, Princess Margaret Cancer Center, 101 College St., Toronto, Ontario, Canada, M5G 1L7 3. Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, Ontario, Canada, M5S 3E1 4. Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University of Toronto, Canada 5. Laboratory of Pathology, National Cancer Institute, Bethesda, MA, USA 6. Toronto Western Hospital, 4-439 West Wing, 399 Bathurst St., Toronto, ON M5T 2S8 Running title: Azoles inhibit HK2 and GBM growth ^ Equal contributing co-authors *Correspondence: Gelareh Zadeh, MD, PhD Associate Professor of Neurosurgery MacFeeters-Hamilton Center for Neuro-Oncology Research, Princess Margaret Cancer Center, 101 College St., Toronto, Ontario, Canada, M5G 1L7 [email protected] Sameer Agnihotri, PhD Assistant Professor of Neurological Surgery Children's Hospital of Pittsburgh University of Pittsburgh School of Medicine Rangos Research Center, 7th Floor, Bay 15 530, 45th Street, Pittsburgh, PA 15201 [email protected] + The authors declare no potential conflicts of interest.
    [Show full text]
  • Fungal Group Fungal Disease Source Guidelines Relevant Articles
    Fungal Fungal disease Source Guidelines Relevant articles Group ESCMID guideline for the diagnosis and management of Candida diseases 2012: 1. Developing European guidelines in clinical microbiology and infectious diseases 2. Diagnostic procedures 3. Non-neutropenic adult patients 4. Prevention and management of Candida diseases ESCMID invasive infections in neonates and children caused by Candida spp 5. Adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT) 6. Patients with HIV infection or AIDS Candidaemia and IDSA clinical practice guidelines 2016 IDSA invasive candidiasis ISPD ISPD guidelines/recommendations Candida peritonitis Peritoneal Dialysis international article Invasive IDSA clinical practice guidelines 2010 IDSA WHO WHO management guidelines Guidelines for the prevention and Cryptococcal treatment of opportunistic infections in AIDSinfo meningitis HIV-infected Adults and adolescents Southern Guideline for the prevention, African diagnosis and management of HIV cryptococcal meningitis among HIV- clinicians infection persons: 2013 update society IDSA IDSA Clinical practice guidelines 2007 Histoplasmosis Guidelines for the prevention and treatment of opportunistic infections in disseminated AIDSinfo HIV-infected Adults and adolescents IDSA IDSA Clinical practice guidelines 2007 Histoplasmosis Guidelines for the prevention and treatment of opportunistic infections in acute pulmonary AIDSinfo HIV-infected Adults and adolescents Invasive IDSA IDSA Clinical practice guidelines 2008 aspergillosis
    [Show full text]